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ABSTRACT 
PURPOSE: To evaluate the effect of a local application of simvastatin gel in repairing bone defects in the femurs of rabbits. 
METHODS: Two standard surgical cavities were created in the femoral epiphysis of 18 rabbits. In the simvastatin group (SG), the 
cavities were filled with a collagen sponge soaked in 0.5 ml of a simvastatin (1 mg) gel, and the cavities were covered with a biological 
membrane. The bone cavities in the second group (control group) were filled with a blood clot and covered with a biological membrane. 
On the 7th, 21st and 42nd days, six animals in each group were euthanized, and the femurs were subject to histological evaluation (vascularity, 
fibrosis, reactive bone formation, osteoblasts, and osteoclasts) and immunohistochemical (anti-VEGF and anti-osteocalcin) analysis. 
The results were analyzed using a Wilcoxon test (p<0.05). 
RESULTS: There were significant differences between the two groups: the SG had greater scores in comparison with the CG in terms 
of the degree of vascularity on the 7th and the 21st days, fibrosis on the 21st day, bone formation reaction on the 21st and the 42nd days 
and the number of osteoblasts and osteoclasts on the 42nd day. The immunohistochemical expression was also greater for osteocalcin 
and VEGF on the 7th, 21st and 42nd days. 
CONCLUSION: Surgical defects created in rabbit femurs were treated locally with simvastatin gel to stimulate bone repair, which 
promoted an ameliorative effect in the morphological and immunohistochemical markers of bone regeneration.
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Introduction
Experimental models of bone regeneration using critical 
defects with no spontaneous regeneration have been used to 
analyze different substances with osteoinductive properties, which 
are specifically able to induce the differentiation of osteoprogenitor 
cells into osteoblasts and induce bone formation1,2. New bone 
formation is triggered by an inducing substance present in the bone 
collagen matrix known as bone morphogenetic protein (BMP)3. 
BMPs are non-collagenous proteins responsible for 
chemotaxis, proliferation of mesenchymal cells, osteoblast 
differentiation and bone formation4,5. Drugs called statins 
have been used for over 30 years to treat hyperlipidemia and 
arteriosclerosis. These drugs may stimulate the expression of 
BMP2 and prevent the prenylation of some GTPase proteins6,7. 
Statins may also stimulate the expression of vascular endothelial 
growth factor (VEGF), which stimulates the differentiation 
of endothelial progenitor cells (EPCs) and, thus, stimulate 
angiogenesis8. Statins also reduce bone resorption and therefore 
inhibit farnesylpyrophosphate (geranilgeranilpirofosfato), which 
is essential for cell differentiation and the function of osteoclasts6. 
However, clinical studies and systematic reviews have shown 
no correlation between the use of oral statins and bone density, 
osteoporosis or the prevention of bone fractures9,10. In vitro studies 
of simvastatin and its local application in experimental bone defects 
has demonstrated, after histological and immunohistochemical 
analyses, that simvastatin increases the expression of the 
growth factors VEGF and BMP2, which are major regulators of 
angiogenesis and osteogenesis11,12. 
A consensus has not yet been reached on the dose of 
simvastatin and the manner in which it should be provided locally. 
Within this context, the objective of this study was to evaluate the 
effect of a local application of simvastatin in the gel state on the 
repair of bone defects in rabbit femurs.
Methods
The experimental protocol (#1913/08) was approved 
by the Ethics Committee of the Sao Paulo Federal University 
(UNIFESP). The study was designed as a randomized, controlled 
trial with a blinded assessment of the outcome. 
Eighteen albino rabbits (Oryctolagus cuniculus), which 
were male, five months old, and weighed 3000 g, underwent 
anesthesia with 0.1 ml of xylazine/kg and 50 mg/kg of ketamine 
injected intramuscularly. A linear 5 cm incision was made in the 
outer left thigh over the femoral epiphysis toward to the caudal 
region. With a digital electric micro-drill, which was under 
continuous saline irrigation and near the epiphysis, two standard 
and non-critical (4 mm diameter and 6 mm deep) bone cavities 
(proximal and distal) were prepared with a 10 mm distance between 
the two cavities. Subsequently, 1 mg of simvastatin gel (0.5 ml) 
mixed with a vehicle of 1% hydroxypropyl methylcellulose (0.5 
ml) was applied. To avoid dispersion of the simvastatin gel and 
to maintain the gel within the bone cavity, we used an absorbable, 
hydrolyzed and lyophilized collagen sponge (Technew-Cod. 
ANVISA n°: 80015520006) as a plug. To prevent invagination of 
non-osteogenic cells in both bone cavities, the cavities were coated 
with a membrane of resorbable bovine bone collagen (GenDerm-
Baumer-Genius Biomaterials - Cod. ANVISA n°: 10345500069).
The animals were randomly assigned to one of two 
groups. In the simvastatin group (SIN), the bone cavity was 
filled with an absorbable collagen sponge (0.02 g) soaked in 0.5 
ml of simvastatin gel (SIN 1 mg / HPMC 0.5 ml) and biological 
membrane collagen. In the control group (CON), the bone cavity 
was filled with a blood clot and biological membrane collagen. 
The wound was sutured with mononylon 4.0. To promote analgesia 
and antimicrobial therapy, the animals received ketoprofen and 
enrofloxacin for five consecutive days. After surgery, the animals 
were randomly assigned into one of three periods of observation: 
seven, 21 or 42 days.
After euthanasia under anesthesia, the left femurs were 
fixed in 10% formalin and were decalcified in trichloroacetic acid 
(5%) for 20 days. Subsequently, each bone was sectioned level with 
the cavity and soaked in paraffin blocks. Finally, four semi-serial 
sections of each block were obtained, and each section was stained 
with hematoxylin and eosin (HE). The histological analysis of the 
slides from each group was performed using light microscopy 
(Axiophot 2, Carl Zeiss Brazil - Sao Paulo-SP). With the help 
of Adobe Photoshop for Windows 1997 (Microsoft - USA), the 
images were transferred to the program ImageJ 1.31p (National 
Institute of Health - USA) and evaluated blindly by the histologist. 
The areas of the bone cavities in each group and sub-group were 
analyzed by scoring and observing the following: vascularity, 
fibrosis, reactive bone formation, osteoblasts and osteoclasts.
For the immunohistochemical study, the sections 
were placed onto slides previously treated with a solution of 
organosilane (3-aminopropyltriethoxysilane, SIGMA, St. Louis, 
MO, USA, cat. 3648) and 20% acetone. Then, the sections 
were placed in an oven maintained at 110°C, subjected to 
deparaffinization in xylene, rehydrated in ethanol and washed in 
distilled water. The histological sections were then incubated with 
primary antibodies diluted in bovine serum albumin (1% BSA in 
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PBS). The antibodies were mouse monoclonal anti-osteocalcin 
to OCG4 (Abcam ab1342) and mouse monoclonal anti-VEGF 
JH121 (ab28775 Abcam). The slides were analyzed by scoring the 
immunoreactivity of the following markers: mouse monoclonal 
OCG4 primary antibody for osteocalcin (ab13421) and mouse 
monoclonal primary antibody JH121 to VEGF (ab28775).
Statistical analysis 
To determine the differences between the two groups 
and between the three observation time periods, the results of the 
descriptive analysis were subject to a nonparametric Wilcoxon 
test (for paired samples), and the level for the rejection of the null 
hypothesis was set at 5% (p<0.05).
Results
Histological evaluation 
At seven days of observation (Figure 1), the semi-
quantitative assessment scores by frequency showed a significant 
presence of neo-vascularization in animals subject to local 
treatment with simvastatin. Other parameters, such as fibrosis, 
osteoblasts and osteoclasts, resulted in scores greater in the 
presence of simvastatin but did not achieve statistical significance. 
Osseous neoformation, as expected in this post-surgical time 
period, was not present in either group. At twenty-one days of 
observation (Figure 2), vascularization was significantly greater 
in the simvastatin group, and simultaneously, there was a greater 
presence of fibrosis and new bone formation in the simvastatin 
group. The scores for the presence of osteoblasts and osteoclasts, 
although greater in the simvastatin group, were not statistically 
significant. At forty-two days of observation (Figure 3), the 
scores for the vascularization and fibrosis did not show significant 
differences, but simvastatin promoted statistically significant 
differences in the score on bone formation and the presence of 
osteoblasts and osteoclasts.
FIGURE 1 - Histological scores for vascularization, fibrosis, bone 
neoformation, osteoblasts and osteoclasts for the simvastatin and the control 
groups at seven days of observation (Wilcoxon test - p<0.05).
FIGURE 2 - Histological scores for vascularization, fibrosis, bone 
neoformation, osteoblasts and osteoclasts for the simvastatin and the control 
group at 21 days of observation (Wilcoxon test - p<0.05).
FIGURE 3 - Histological scores for vascularization, fibrosis, bone 
neoformation, osteoblasts and osteoclasts for the simvastatin and the control 
groups at 42 days of observation (Wilcoxon test - p<0.05).
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Immunohistochemistry evaluation
At seven days of observation, there was a significant 
presence of VEGF, which matched the greater frequency of 
neovascularization observed from the HE staining. At twenty-one 
days, the VEGF was not statistically significant, which was unlike 
the osteocalcin, which was significantly more prevalent at this 
time. At forty-two days, the two markers did not show differences 
between the groups (Figure 4).
of rabbit bone repair is completed in approximately 42 days16. 
Therefore, the evaluation carried out in periods of seven, 21 and 
42 days allowed for the analysis of the initial, intermediate and 
final stages of bone repair15,16.
Our animal model created a bone defect that was 
regarded as a non-critical injury (4 mm diameter and 6 mm deep) 
and only removed the cortical layer. It was a defect that the body 
would be able to spontaneously repair by replacing the defect with 
new bone tissue without the need for some type of treatment. The 
purpose was to verify that the use of an osteoinductive material 
could shorten the time needed to repair the defect.
The femoral epiphysis has characteristics suitable for the 
preparation of cavities because it presents red bone marrow with a 
large amount of spongy bone and osteoprogenitor cells. Furthermore, 
the epiphysis of the femur allows for the creation of a defect with 
a larger diameter and depth without increasing the risk of fracture. 
With a trephine having a 4.0 mm diameter, it was possible to prepare 
two cavities in each femoral epiphysis with a minimal risk of hip 
fracture, which, in fact, did not occur in any animal.
Simvastatin is characterized as a lipophilic statin that 
can passively penetrate the cell membrane and exert its effect at 
the tissue level. We applied the simvastatin in gel form through 
an association with a vehicle: hidroxipropilenometilcelulose 
(HPMC), which is biocompatible, stable and able to slowly release 
simvastatin in its action site. The choice of the concentration of 
simvastatin (1.0 mg / ml gel 0.5 HPMC) was based on other reports 
that used similar doses: 2.2 mg17, 0.5 mg11,18, 0.1 mg / 0.5 mg / 1.0 
mg / 1.5 mg / 2.2 mg19. There are reports that the local use of high-
dose simvastatin impaired bone healing, which suggests that there 
might have been a stimulant effect on osteoclastic activity, which 
would result in the resorption of new bone formations9.
The success of bone repair depends on the permanence 
time and on the absorption of the material at the site of the 
bone defect20,21. The absorbable collagen sponge allowed the 
simvastatin gel to remain in the bone cavity, while not interfering 
with the drug’s action11,18. A physical barrier (osteo promoter) was 
positioned and was composed of a resorbable collagen membrane 
overlying the opening of the bone defect with the intent of retaining 
the soft tissue and, thus, allowing only the cells originating from 
the bone tissue to occupy the area of the lesion.
Some authors did not observe new bone formation induced 
by simvastatin22-24. Other reports indicate that simvastatin17,25-28 
influenced and stimulated new bone formation. There are few 
consistent studies on the anabolic effects and bioavailability 
of simvastatin, which is a fact that leads to such varying results 
among several studies29.
FIGURE 4 - Immunohistochemical scores for VEGF and osteocalcin for 
the simvastatin and the control group at 21 days of observation (Wilcoxon 
test - p<0.05).
Discussion
The development of new biomaterials has been conducted 
with the aim of identifying new methods of stimulating cytokines 
and growth factors focused on osteoinductive, osteoconductive 
and angiogenic actions. These biomaterials need to be easy to 
manipulate, be absorbable and have a physical structure capable 
of maintaining a space for bone formation without generating an 
appreciable immune response. Despite major advances in science 
and technology, there is not a substance that meets the majority of 
these requirements13,14.
Bone defects have been used as experimental models for 
the study of bone regeneration because the repair of these defects 
resembles the direct repair of fractures. Other models have been 
reported using animals, such as rats, rabbits, cats, dogs, pigs, 
monkeys, and have been conducted using bone defects in the 
calvaria, the jaw or in long bones15.
The rabbit model has the advantage that it is easy to 
handle the animals and allows for larger bone defects compared 
with rats, mice or guinea pigs. The exclusive use of males avoided 
the possible hormonal changes present in females because this 
could compromise the results. There is a consensus that the cycle 
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The results obtained in this study for the period of seven 
days, which is considered to be the initial phase of bone healing, 
showed increased vascularity with a significantly greater amount of 
newly formed vessels in the simvastatin group compared with the 
control group (Figure 1). There was also a statistically significant 
greater antibody immunostaining for VEGF in the simvastatin 
group compared with the control group (Figure 4). These results 
are in agreement with other studies11,12,18, and it can be inferred 
that, in the acute phase of bone repair, simvastatin had a beneficial 
effect on stimulating the production of new vessels, which might 
reflect an advantage for subsequent stages of bone regeneration.
For the other variables, even with greater mean and 
median values in the simvastatin group, no significant difference 
was observed between the groups. It is possible that further study 
with a larger sample or a different marker of greater sensitivity 
can demonstrate the trend observed in these favorable results with 
the use of simvastatin. Slight fibrosis and no new bone formation 
was observed, which is to be expected at this stage. The moderate 
immunostaining for osteocalcin is also expected as there has not 
been sufficient stimuli for osteocalcin’s manifestation, which 
should occur in the later stages of the process. The large amount of 
osteoclasts and moderate amounts osteoblasts were consistent with 
other reports in the literature11,12,18, which demonstrates the need 
for removing the remaining bone debris before the proliferation 
of osteoblasts and deposition of bone matrix, which is driven by 
osteocalcin.
After twenty-one days, we observed an intense fibrosis, 
and there was increased formation of dense connective tissue 
rich in collagen fibers in the simvastatin group compared with 
the control group. There was also moderate vascularization and 
early bone formation with greater scores in the simvastatin group 
compared with the control group (Figure 4). Greater expression 
for the osteocalcin antibody in the simvastatin group was found 
compared with the control group. There are reports that coincide 
with these data30,31. Additionally, at twenty-one days in the 
intermediate phase of bone regeneration, simvastatin showed 
favorable effects by stimulating a greater presence of connective 
tissue and vessels as well as a greater stimulation of the bone 
matrix by osteocalcin.
For the other variables, although the mean was identical 
and the median was greater in the simvastatin group, there was no 
statistically significant difference between the groups with slight 
immune-staining for VEGF, large amounts of osteoblasts and 
moderate amounts of osteoclasts. Again, a larger sample size or a 
more sensitive marker may help to confirm this favorable trend for 
the use of simvastatin in future studies.
During the forty-two day observation period, we 
documented an intense reactive bone formation as well as greater 
scores for bone tissue formation in the simvastatin group compared 
with the control group (Figure 3). More osteoblasts were observed 
with greater scores in the simvastatin group compared with the 
control group (Figure 3). The same occurred with the osteoclasts with 
greater scores in the simvastatin group compared with the control 
group. These results are in agreement with other studies16-19,26. In 
the late period of regeneration, simvastatin was able to stimulate a 
greater presence of osteoblasts and subsequent bone formation. 
The remaining variables showed no statistically 
significant difference between the groups, but we observed discrete 
neovascularization in the two groups and moderate fibrosis still 
present in the control group. Intense and greater immune-staining 
for osteocalcin antibody in the simvastatin group was observed 
compared with the control group as well as mild immune-staining 
for VEGF in both groups (Figure 4).
Given the results, the proposed model of topical 
application of the simvastatin proved to be efficient and effective. 
The applied drug was stable and persisted in cavities that were 
made in the femurs of rabbits, which shows that this method of 
offering the drug should be studied in more detail in the future. 
Moreover, the beneficial effects of simvastatin have been shown at 
different stages during the biological process of bone repair. At the 
7th day, simvastatin’s effect was greatly expressed in stimulating 
vascularization, and this time point is the crucial point of the 
acute phase. Fibroblast proliferation and marked bone formation 
was observed on the 21th day and persisted to the 42nd day with a 
significant expression of osteoblasts and osteoclasts.
Conclusion
Surgical defects created in rabbit femurs were treated locally 
with simvastatin gel to stimulate bone repair, which promoted an 
ameliorative effect in the morphological and immunohistochemical 
markers of bone regeneration.
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